Analysts Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $107.33

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $107.3333.

Several brokerages have recently weighed in on ANIP. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Finally, Guggenheim raised their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th.

Insider Activity

In other news, SVP Ori Gutwerg sold 2,060 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $76.50, for a total transaction of $157,590.00. Following the completion of the transaction, the senior vice president directly owned 84,782 shares in the company, valued at $6,485,823. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen P. Carey sold 7,312 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $75.50, for a total value of $552,056.00. Following the sale, the chief financial officer directly owned 185,543 shares in the company, valued at $14,008,496.50. This trade represents a 3.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 27,860 shares of company stock valued at $2,111,581. 11.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Pacer Advisors Inc. boosted its position in shares of ANI Pharmaceuticals by 1,821.1% during the fourth quarter. Pacer Advisors Inc. now owns 79,919 shares of the specialty pharmaceutical company’s stock valued at $6,309,000 after buying an additional 75,759 shares during the last quarter. Invesco Ltd. boosted its position in shares of ANI Pharmaceuticals by 26.0% during the fourth quarter. Invesco Ltd. now owns 189,836 shares of the specialty pharmaceutical company’s stock valued at $14,986,000 after buying an additional 39,178 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at $1,243,000. Susquehanna Portfolio Strategies LLC purchased a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at $906,000. Finally, Tang Capital Management LLC boosted its position in shares of ANI Pharmaceuticals by 51.6% during the fourth quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock valued at $38,005,000 after buying an additional 163,937 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $80.92 on Thursday. ANI Pharmaceuticals has a 1-year low of $56.71 and a 1-year high of $99.50. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. The business has a fifty day moving average price of $76.14 and a 200-day moving average price of $81.93. The company has a market capitalization of $1.81 billion, a PE ratio of 24.08 and a beta of 0.44.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.